Abstract library

36 results for "Meyer".
#936 Promoter Hypermethylation at RASSF1 is a Feature of Small Intestinal Neuroendocrine Tumors
Introduction: Promoter hypermethylation of RASSF1 has been reported in many tumor types.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
#1227 Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)
Introduction: Aberrant DNA methylation plays an role in the pathogenesis of many cancers, however little is known about its role in SINET development.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#205 Integrated Genome-Wide DNA Methylation and mRNA Expression Analysis of Pancreatic NETs Identifies Differential Activation of the Hypoxia Inducible Factor (HIF) Pathway Between Low and Intermediate Grade Tumors
Introduction: This is the first study to integrate DNA methylation and mRNA expression analysis in NETs. It is a powerful approach with which to identify disrupted biological pathways in NET pathogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#244 Challenges in the Management of VIPoma Patients
Introduction: VIPomas are a rare neuroendocrine tumor (NET). 90% are pancreatic. 40-70% are metastatic at presentation. The VIPoma syndrome is characterized by secretory diarrhoea, hypokalaemia and achlorhydria.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly
#250 Circulating Tumor Cells (CTCs) Correlate with Overall Survival in Neuroendocrine Tumors (NETs)
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated. We have previously shown that CTCs are detectable in NETs and associated with progressive disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#251 Ki-67 is a Better Prognostic Marker than Mitotic Count in Neuroendocrine Tumors
Introduction: The recent classification system proposed by ENETS assigns grade by Ki-67 index +/- mitotic count. It has been adopted into routine practice but there is limited data on the relationship between them.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#440 The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing – MeDIP-seq
Introduction: Recently, the first cancer methylomes have been created which identified differential methylation at CpG island-shores (2kb upstream of CpG islands) to be of particular importance in the tumourigenic process.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors: Thirlwell C, Sasmaz S, Dibra H, Feber A, ...
#489 Goblet Cell Appendiceal Neuroendocrine Tumors: Diagnosis, Recurrence Rates, Treatment and Survival. A Series of 37 Patients
Introduction: Goblet cell appendiceal neuroendocrine tumors (GCA-NETs) share histologic features of both adenocarcinomas and NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Christos Toumpanakis
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.